(1,3) β-D-Glucan (BDG) is present in the cell wall of most fungi. Its detection in serum has been useful in the diagnosis of invasive aspergillosis (IA) in patients with hematologic malignancies. However, assaying for BDG did not perform well in the serum of lung transplant recipients. We undertook to study the performance of BDG in the bronchoalveolar lavage (BAL) of lung transplant recipients for the diagnosis of invasive pulmonary aspergillosis (IPA). Available and stored BAL samples from lung transplant recipients at the Toronto General Hospital between October 2007 and April 2013 were tested for BDG using the Fungitell kit from the Associates of Cape Cod Inc, Falmouth, MA, USA. The International Society for Heart and Lung transplantation (ISHLT) criteria was used for the diagnosis of IA. Of 195 samples, there were ten episodes of IA. The sensitivity and specificity of the test were 80% and 53% and 60% and 70% at 41 pg/ml and 108 pg/ml cut-offs, respectively. On excluding 52 bronchoscopies due to receipt of anti-Aspergillus therapy during specimen collection, the sensitivity and specificity improved to 75% and 91%, respectively, at a 524 pg/ml cut-off. However, only four episodes of IA remained in this analysis. Using BDG in BAL of lung transplant recipients for the diagnosis of IA, our study demonstrated moderate sensitivity and specificity.
Introduction
Invasive fungal infections (IFIs) constitute a major problem among immunocompromised individuals. Among the solid organ transplant recipients, lung transplant recipients have the highest risk of fungal infections with an incidence rate of 8.6% in the first year after transplantation. 1 IA is the most common fungal infection followed by invasive candidiasis in lung transplant patients. 2 Non-culture-based markers for the diagnosis of IFIs have certainly improved the diagnosis and may have affected the mortality of IFI. 3, 4 However, the search for the perfect diagnostic test continues. BDG is a cell wall component of most fungi except Zygomycetes and Cryptococcus. It has been studied in the serum for the diagnosis of many IFIs. Based on a metaanalysis, the sensitivity and specificity of serum BDG for the diagnosis of Pneumocystis jirovecii, invasive candidiasis, and IA are 96% and 84%, 81% and 81%, and 77% and 83%, respectively. 5 Most of the patients in this metaanalysis had hematologic malignancies. Although serum BDG performed relatively well in these patients, it has a modest diagnostic capability for the diagnosis of IA in lung transplant patients. The test had a sensitivity of 71% and a specificity of 59% in a study by Alexander et al. in lung transplant recipients. 6 IA commonly involves lungs; therefore, BAL may be a preferable specimen over serum. This has been substantiated previously by better diagnostic characteristics of Aspergillus galactomannan in BAL than serum of lung transplant patients. 7 We hypothesized that BDG in BAL will have better diagnostic accuracy than the reported values in serum for the diagnosis of IPA in lung transplant recipients.
Materials and methods
The study was approved by the Research Ethics Board of the institution (REB -approval no. 13-7225-AE). Consecutive lung transplant recipients with stored BAL in adequate quantities for BDG testing at the Toronto General Hospital, Toronto, Ontario, Canada were included in the study.
Data collection
The following patient data were collected for the study: demographics, underlying lung disease, type of lung transplant and CMV donor/recipient status, hemodialysis, and receipt of intravenous immunoglobulin within a week of bronchoscopy. Specific data on the date of BAL sample collection were also gathered. These included but not limited to indications for bronchoscopy, bronchoscopy findings, BAL microbiology results, pathology, and receipt of pipericillin-tazobactam and anti-Aspergillus therapy. Radiological findings up to seven days prior to and two days after the bronchoscopy date were collected.
Storage of samples
After collection, BAL samples were promptly aliquoted and stored in a −70 degree freezer. The detailed protocol for collection and processing of samples is reported elsewhere. 8 
BDG testing
The Fungitell kit from Associates of Cape Cod Inc, Falmouth, MA, USA was utilized for BDG testing. Manufacturer recommendations were followed for performing the test. Results were read from <31 to >523 pg/ml. Random samples were tested in duplicate to verify testing methodology and results.
Definitions
The ISHLT criteria for the diagnosis of IA was utilized. 9 Proven and probable IA according to the aforementioned criteria were categorized as IA. The personnel involved in categorizing the cases were blinded to the BAL BDG result. Peripheral white blood cell count, fever, and symptoms were not taken into consideration due to difficulty in gathering this information. The Bio-Rad Platelia TM Aspergillus antigen kit was used for Aspergillus galactomannan testing in the BAL fluid. A 0.5 cut-off was considered positive. Serum Aspergillus galactomannan was not routinely done in lung transplant patients in our institution. Anti-Aspergillus therapy was defined as receipt of itraconazole, caspofungin, inhaled and intravenous amphotericin B in any formulation, voriconazole, or posaconazole.
The immunosuppressive induction and maintenance regimen, treatment for rejection 10 and antifungal prophylaxis strategies 11 in our lung transplant patients have been reported in detail elsewhere.
10,12

Statistical analysis
Since all observations within a patient (BDG tests in the context of this study) were correlated, we used the random effect generalized estimating equation (GEE) model for correlation of multiple observations from the same subject. 13 Receiver operative characteristic (ROC) curves were generated to determine the optimal cutoff for the test. 
Results
One hundred and ninety five BAL samples from 107 lung transplant patients were available for BDG testing and included in the study. The dates of sample collection in these Table 1 lists the characteristics of the patients, their bronchoscopy, microbiology, radiology, and medication data. The median age of lung transplant recipients was 54 years (IQR 34-63). Majority of the BAL samples had concomitant bacterial, mycobacterial, fungal cultures and Aspergillus galactomannan testing done. Fifteen (8%) bronchoscopy notes were not available, and therefore Aspergillus tracheobronchitis (TrB) could not be truly assessed for these episodes. Twenty-seven percent of BALs were performed while patients were on anti-Aspergillus therapy, which could have affected the BDG results. Of the 195 samples, there were ten IA events in eight patients. Seven of these ten bronchoscopies were done for surveillance purposes. All the IA events were probable cases. There were three episodes of pulmonary IA, four episodes of invasive Aspergillus TrB, and three episodes of both IPA and TrB. Nine of ten BALs grew Aspergillus species, and the tenth event had a positive BAL Aspergillus galactomannan without culture positivity (Table 2) . Table 3 lists the mutually exclusive fungal diagnoses events of: IA, respiratory colonization with: Aspergillus only, mold other than Aspergillus only, yeast only, mixed fungal and no fungal respiratory colonization. Of the ten events with IA, five had other fungal respiratory colonization: two each with yeast and Penicillium and one with Exophiala dermatitidis. There were no events of pulmonary IFIs other than IA in this study. The median value of BAL BDG was 40 pg/ml (IQR 30-140) in whole cohort. Figure 1 displays the median BAL BDG values with their IQR for the different fungal diagnosis events. The median duration of anti-Aspergillus therapy in these patients prior to bronchoscopy was 49 days (IQR 25-87). The median value of BDG for IA was higher (232 pg/ml; IQR 41-524; P = .31) compared to other fungal diagnoses. However, BDG values were not different between IA and Aspergillus colonization (232 pg/ml vs. 94 pg/ml; P = .28). When BDG values among patients with IPA or AspTrB were compared, they were not statistically different (363 vs. 178; P = .38). When 52 bronchoscopy events were excluded (where the patients were on anti-Aspergillus therapy on the day of bronchoscopy) ( Figure 2 ), the median BAL BDG value was no different in IA (524 pg/ml; IQR 277-524) compared to with and without fungal respiratory colonization (P = .11). Similarly, BAL BDG values were no different among patients with fungal colonization (41 pg/ml; IQR 30-240) as compared to no fungal colonization (30 pg/ml; IQR 30-93; P = .09) when patients with IA were excluded from analysis. Two patients with five BDG values had received the intravenous immunoglobulin therapy when the bronchoscopy was done. First patient (three BDG values) had persistent nonresolving Aspergillus flavus pneumonia, while the second patient had positive galactomannan in the BAL. Only two patients in this cohort were receiving hemodialysis: one patient had positive galactomannan without any radiological evidence of diseases, while the other patient was noted to have Aspergillus colonization.
The ROC analysis was undertaken to determine the BDG optimal cut-off for the diagnosis of IA. At 41 pg/ml cutoff, the sensitivity of the test was 80%, but the specificity was only 53%. Increasing the cut-off to 108 pg/ml, the specificity improved to 70% but the sensitivity declined to 60% (Tables 4 and 5 ). After excluding the 52 bronchoscopies who had received anti-Aspergillus therapy on bronchoscopy day, the sensitivity and specificity were 75% and 91%, respectively, at 524 pg/ml cut-off. However, only four episodes of IA remained in this analysis.
We also compared the BDG values among alive and deceased patients at 12 weeks. The median value of BDG among alive and deceased patients at 12 weeks were 37.5 pg/ml (IQR 30-140) and 62 pg/ml (IQR 53-88), respectively (P = .57).
Discussion
Diagnosis of IA in lung transplant recipients remains challenging. However, the diagnosis of IA is not solely dependent on the presence of biomarker or culture positivity. The most commonly used criteria by the European Organization for Research and Treatment (EORTC)/Mycoses Study Group (MSG), recommend clinical, microbiological, radiological, and histological domains to determine the certainty of diagnosis (proven, probable, possible). It is to be noted, however, that these criteria were specifically established for the patients with hematological malignancy. These definitions fail to address the unique nature of clinical syndromes in lung transplant recipients, (colonization, TrB, and bronchial anastomotic infections), lack of classical radiological presentation as seen in neutropenic patients (halo sign), as well as differences in the sensitivity of serological tests, particularly galactomannan in lung transplant recipients. Additionally, the category of possible fungal infection might not be applicable in lung transplant recipients owing to a multitude of possible diagnosis in these patients. We have therefore chosen to utilize the ISHLT definitions that take into account the unique nature of lung transplant recipients.
Indeed the use of galactomannan in BAL has significantly improved the diagnosis, but it remains far from ideal.
3 BDG is another biomarker that can detect Aspergillus in addition of other fungi and has been used as a screening tool at some centers for high risk patients. 6 We had hypothesized that BAL BDG in lung transplant recipients will perform well in the diagnosis of IPA. However, in our study at 41 pg/ml and 108 pg/ml cut-offs, the test showed moderate sensitivity (80%, 53%) and poor specificity (53%, 60%) for the diagnosis of IA. The sensitivity and specificity improved to 75% and 91%, respectively, after exclusion of patients on anti-Aspergillus therapy. Our finding of moderate sensitivity and low specificity is in conformity with a recently reported study that evaluated BAL BDG for the diagnosis of IFI in all solid organ transplant recipients of which 85% were lung transplant recipients. At 100 pg/ml cut-off, the sensitivity and specificity of the test were 80% and 38%, respectively.
14 It appears that all their patients had been initiated on antifungal therapy prior to bronchoscopy. Hence it is difficult to draw robust conclusions regarding the true test characteristics. Moreover, we used the random effect GEE model for the calculation of sensitivity and specificity which accounts for autocorrelation. Several studies have evaluated BAL BDG in hematology patients where sensitivity and specificity ranged from 50-80% and 55-80%, respectively. [15] [16] [17] None of these studies report the performance of the test in anti-fungal therapy naïve patients although one study 17 did find that receipt of anti-fungal therapy led to false negative BDG results in BAL. In our study excluding these patients led to significant improvement in the diagnostic characteristics of the test. This was predominantly because of the exclusion of six events with IA who were on anti-mold therapy and had lower levels of BDG in BAL. In the BAL BDG studies in hematology patients, 15-17 the fungitell kit was used with a serum cut-off 80 pg/ml. That might not be an appropriate cut-off in BAL, since the fungal burden in the lung compartment is likely to be higher than serum. This is substantiated by higher BDG cut-off values in BAL in our study compared to serum (60 pg/ml) reported in lung transplant patients. 6 There was a higher rate of positive BAL BDG results in our study. Sixty-three percent (35/55) of the BALs at the 108 pg/ml cut-off were noted to have positive fungal colonization, which is common in lung transplant recipients. Thirty-six percent (20/55) had no growth of fungal organisms in BAL at the same cut off. The interpretation of these samples may be difficult as this may represent lower sensitivity of fungal culture in BAL. Intravenous immunoglobulin, albumin, intravenous amoxicillin-clavulanic acid, bacteremia, use of surgical gauze, and hemodialysis with cellulose membranes have been associated with false positive serum BDG results. 18 No association was found between antiinfective treatment and false positive BAL BDG results. We are not aware of other factors that may have caused false positive BAL BDG results. We could not collect data on albumin administration or the use of surgical gauze due to unreliable documentation of these in our electronic medical record. Therefore, in our study we could not completely explain the reasons for false positive BAL BDG results. We did not find any association of higher BDG values with three months mortality as reported previously. 19 However, it is to be noted that there were only eight solid organ transplant recipients in that study. Moreover, the AUC for 90-day mortality was 0.652 (95% CI 0.574-0.730; P = .001) suggesting relatively moderate discriminatory power. It is also plausible that having only five patients, who died within 90 days, we may not have enough power to perform this analysis. There are several limitations to our study that need to be acknowledged. The data on the sensitivity and specificity of the whole cohort should be interpreted with caution as there were a small number of cases with IA. Since the inclusion criterion in our study was the availability of stored BAL samples in adequate quantities (convenient sampling), sequential BAL samples may not have been used. Importantly, initial BAL sample associated with the diagnosis of IA was not available in half the patients with IA in our cohort. This also explains why many patients with IA were already on anti-Aspergillus therapy at the time of bronchoscopy. However, to overcome this shortcoming we analyzed the data after excluding patients who were receiving anti-Aspergillus therapy. Another limitation is the non-availability of data regarding the stability of BDG in BAL over time. However, 170 of 195 samples were collected in the latter years between 2011 and 2013 and there was no correlation between the date of sample collection and BAL BDG values. Finally, the application of our data may be limited as in fact few IA events remained when those cases of positive BDG in patients on anti-Aspergillus therapy were excluded.
In our study we have possibly identified a cause, receipt of anti-Aspergillus therapy, for the poor performance of BDG in BAL reported in earlier studies. However, it is difficult to draw firm conclusions because of the small number of IA events (numbering four) that remained in our subset analysis. Therefore, future studies with a higher event rate (IA) in antifungal therapy naive patients can confirm the usefulness of this test for the diagnosis of IA in lung transplant recipients. Furthermore, teasing out the causes for false positive results may make BAL BDG on surveillance bronchoscopies a valuable tool for preemptive antifungal therapy in lung transplant patients.
BAL (1,3) BDG had a modest sensitivity and specificity in our study for the diagnosis of IPA in lung transplant recipients. However, the test performance improved markedly in anti-Aspergillus therapy naïve patients. Nonetheless, the small number of IA cases that remained for the analysis precludes us from forming definitive conclusions.
